Patent classifications
C07D275/03
A KIND OF ISOTHIAZOLE OXIME ETHER-CONTAINING STROBILURIN DERIVATIVES AND ITS PREPARATION METHODS AND APPLICATION
The present invention is that provided a synthesis method of a series of isothiazole oxime ether-containing strobilurin derivatives IV. The present invention relates to 3,4-dichloroisothiazolyl oxime ether strobilurin derivatives, and their chemical structural formula is as shown by IV.
##STR00001##
The invention discloses the structural formula of the above compound, the synthesis method and the use as an insecticide, a fungicide, an anti-plant virus agent, and an agriculturally acceptable auxiliary or synergist and a commercial insecticide. The use of a fungicide, an anti-plant virus agent and an acaricide in combination for controlling agricultural, forestry, horticultural plant pests, diseases, virus diseases and preparation methods.
NOVEL FLAVORS, FLAVOR MODIFIERS, TASTANTS, TASTE ENHANCERS, UMAMI OR SWEET TASTANTS, AND/OR ENHANCERS AND USE THEREOF
The present invention relates to the discovery that certain non-naturally occurring, non-peptide amide compounds and amide derivatives, such as oxalamides, ureas, and acrylamides, are useful flavor or taste modifiers, such as a flavoring or flavoring agents and flavor or taste enhancer, more particularly, savory (the umami taste of monosodium glutamate) or sweet taste modifiers,savory or sweet flavoring agents and savory or sweet flavor enhancers, for food, beverages, and other comestible or orally administered medicinal products or compositions.
AMANITA MUSCARIA EXTRACTS AND COMPOUNDS AND THEIR BENEFICIAL AND THERAPEUTIC USE
Provided are beneficial and therapeutic Amanita muscaria compositions. In some embodiments, the provided A. muscaria compositions comprise A. muscaria extracts. In some embodiments, the provided A. muscaria compositions comprise one or more compounds from A. muscaria such as muscimol and muscarine, as well as analogs thereof. In some aspects, the provided A. muscaria compositions are used to promote health and wellness, such as to enhance calmness in a subject. In some aspects, the provided A. muscaria compositions are used to treat mental health conditions and physical health conditions in a subject.
AMANITA MUSCARIA EXTRACTS AND COMPOUNDS AND THEIR BENEFICIAL AND THERAPEUTIC USE
Provided are beneficial and therapeutic Amanita muscaria compositions. In some embodiments, the provided A. muscaria compositions comprise A. muscaria extracts. In some embodiments, the provided A. muscaria compositions comprise one or more compounds from A. muscaria such as muscimol and muscarine, as well as analogs thereof. In some aspects, the provided A. muscaria compositions are used to promote health and wellness, such as to enhance calmness in a subject. In some aspects, the provided A. muscaria compositions are used to treat mental health conditions and physical health conditions in a subject.
ADDITIVE FOR NON-AQUEOUS ELECTROLYTE, NON-AQUEOUS ELECTROLYTE, AND POWER STORAGE DEVICE
An additive for a non-aqueous electrolyte solution including a compound represented by the following formula (A1) or (A2).
##STR00001##
In the formula, X.sup.a represents a group that forms a cyclic group together with a nitrogen atom, Z.sup.a1 and Z.sup.a2, Z.sup.a1 and Z.sup.a2 each independently represent a sulfonyl or carbonyl group, R.sup.a1 represents an optionally substituted alkylene group of 1 to 4 carbon atoms, an alkenylene group of 3 or 4 carbon atoms or an alkynylene group of 3 or 4 carbon atoms, R.sup.a2 represents a hydrogen atom, a halogen atom or an optionally substituted alkyl group of 1 to 4 carbon atoms, R.sup.a3 represents oxygen or an optionally substituted alkylene group of 1 to 4 carbon atoms, alkenylene group of 3 or 4 carbon atoms or alkynylene group of 3 or 4 carbon atoms.
ADDITIVE FOR NON-AQUEOUS ELECTROLYTE, NON-AQUEOUS ELECTROLYTE, AND POWER STORAGE DEVICE
An additive for a non-aqueous electrolyte solution including a compound represented by the following formula (A1) or (A2).
##STR00001##
In the formula, X.sup.a represents a group that forms a cyclic group together with a nitrogen atom, Z.sup.a1 and Z.sup.a2, Z.sup.a1 and Z.sup.a2 each independently represent a sulfonyl or carbonyl group, R.sup.a1 represents an optionally substituted alkylene group of 1 to 4 carbon atoms, an alkenylene group of 3 or 4 carbon atoms or an alkynylene group of 3 or 4 carbon atoms, R.sup.a2 represents a hydrogen atom, a halogen atom or an optionally substituted alkyl group of 1 to 4 carbon atoms, R.sup.a3 represents oxygen or an optionally substituted alkylene group of 1 to 4 carbon atoms, alkenylene group of 3 or 4 carbon atoms or alkynylene group of 3 or 4 carbon atoms.
NOVEL SULFONYLAMINOBENZAMIDE COMPOUNDS AS ANTHELMINTICS
The present invention relates to a new compound of formula (I) wherein the variables have the meaning as indicated in the claims; or an enantiomer or salt thereof. The compounds of formula (I) are useful in the control of parasites, in particular endoparasites, in and on vertebrates.
##STR00001##
NOVEL SULFONYLAMINOBENZAMIDE COMPOUNDS AS ANTHELMINTICS
The present invention relates to a new compound of formula (I) wherein the variables have the meaning as indicated in the claims; or an enantiomer or salt thereof. The compounds of formula (I) are useful in the control of parasites, in particular endoparasites, in and on vertebrates.
##STR00001##
COMPOUNDS, COMPOSITIONS, AND METHODS OF MAKING AND USING THE SAME
Compounds are provided according to Formula (I), and hydrates thereof, and compositions thereof; and methods of using and making the same. Compounds of the present invention are contemplated useful for suppressing pain during cosmetic, medical, and dental procedures. In another aspect, provided herein is a composition comprising the compound of Formula (I) or hydrate thereof and a pharmaceutically acceptable carrier.
FARNESOID X RECEPTOR AGONISTS AND USES THEREOF
Described herein are compounds that are farnesoid X receptor agonists, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders associated with farnesoid X receptor activity.